Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.
Mikkilineni L, Natrakul DA, Lam N, Manasanch EE, Mann J, Weissler KA, Wong N, Brudno JN, Goff SL, Yang JC, Ganaden M, Patel R, Zheng Z, Gartner JJ, Martin KR, Wang HW, Yuan CM, Lowe T, Maric I, Shao L, Jin P, Stroncek DF, Highfill SL, Rosenberg SA, Kochenderfer JN. Mikkilineni L, et al. Mol Ther. 2024 Feb 7;32(2):503-526. doi: 10.1016/j.ymthe.2023.12.018. Epub 2023 Dec 28. Mol Ther. 2024. PMID: 38155568
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, Fromm GC, Patel R, Pittaluga S, Kochenderfer JN. Brudno JN, et al. Among authors: mikkilineni l. Blood Adv. 2024 Feb 13;8(3):802-814. doi: 10.1182/bloodadvances.2023011470. Blood Adv. 2024. PMID: 37939262 Free PMC article. Clinical Trial.
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.
Epperly R, Giordani VM, Mikkilineni L, Shah NN. Epperly R, et al. Among authors: mikkilineni l. Hematol Oncol Clin North Am. 2023 Dec;37(6):1169-1188. doi: 10.1016/j.hoc.2023.05.010. Epub 2023 Jun 21. Hematol Oncol Clin North Am. 2023. PMID: 37349152 Review.
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.
Faruqi AJ, Ligon JA, Borgman P, Steinberg SM, Foley T, Little L, Mackall CL, Lee DW, Fry TJ, Shalabi H, Brudno J, Yates B, Mikkilineni L, Kochenderfer J, Shah NN. Faruqi AJ, et al. Among authors: mikkilineni l. Blood Adv. 2022 Dec 13;6(23):6040-6050. doi: 10.1182/bloodadvances.2022007676. Blood Adv. 2022. PMID: 35939781 Free PMC article.
CAR T cell therapies for patients with multiple myeloma.
Mikkilineni L, Kochenderfer JN. Mikkilineni L, et al. Nat Rev Clin Oncol. 2021 Feb;18(2):71-84. doi: 10.1038/s41571-020-0427-6. Epub 2020 Sep 25. Nat Rev Clin Oncol. 2021. PMID: 32978608 Review.
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: mikkilineni l. Nat Med. 2020 May;26(5):803. doi: 10.1038/s41591-020-0864-x. Nat Med. 2020. PMID: 32291416 Free PMC article.
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: mikkilineni l. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959992 Free PMC article. Clinical Trial.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. Zimmer AS, et al. Among authors: mikkilineni l. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3. J Immunother Cancer. 2019. PMID: 31345267 Free PMC article. Clinical Trial.
14 results